71 results on '"Strom, T B"'
Search Results
2. Allogeneic stem cells, clinical transplantation, and the origins of regenerative medicine.
3. Death of alloreactive T cells sets the stage for immunoregulation to act.
4. Blockade of CD40L/CD40 costimulatory pathway in a DST presensitization model of islet allograft leads to a state of Allo-Ag specific tolerance and permits subsequent engraftment of donor strain islet or heart allografts.
5. T-cell growth factors in allograft rejection and tolerance.
6. Immunoglobulin-cytokine fusion molecules: the new generation of immunomodulating agents.
7. Quantitative competitive polymerase chain reaction: design and synthesis of mRNA-specific competitor DNA templates and their clinical usage.
8. Adjusting immunosuppression to the identification of T-cell activating mediators in rejecting transplants: a novel approach to rejection diagnosis and treatment.
9. CTL effector mechanisms: diagnostic applications.
10. Molecular correlates of human renal allograft rejection.
11. IL-2 and IL-4 double knock-out mice reject islet allografts: a role for novel T-cell growth factors?
12. Interleukin-15 gene transcripts are present in rejecting islet allografts.
13. Rapamycin and cyclosporine A treatment: a novel regimen to prevent chronic allograft rejection in sensitized hosts.
14. Use of intragraft gene expression in the diagnosis of kidney allograft rejection.
15. Successful pancreas-renal transplantation without anti-T-cell antibody induction.
16. Genetically engineered proteins for immunoregulation.
17. Cytokine and alloantibody networks in long-term cardiac allografts in rapamycin-treated sensitized rat recipients.
18. Summation of the biologic aspects of the congress.
19. Interleukin-2 receptor signal transduction: translocation of active serine-threonine kinase Raf-1 from IL-2 receptor into cytosol depends on IL-2-induced tyrosine kinase activation.
20. Analysis of cytokine transcripts in pancreatic islet cell allografts during rejection and tolerance induction.
21. Sequential analysis by polymerase chain reaction of mononuclear leukocyte activation-associated transcription in pancreatic islet cell allograft rejection.
22. Interleukin-7 (IL-7) and its effect on the expression of the intercellular adhesion molecule (ICAM-1) in T cells.
23. Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus-immune globulin: comparison of the randomized and open-label trials.
24. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation.
25. The immunopharmacology of graft rejection.
26. Suppressor cells in enhancement of organ allografts.
27. Mechanisms of cardiac allograft prolongation by cyclosporin-A.
28. Early experience with anti-Tac in clinical renal transplantation.
29. Monoclonal anti-IL-2 receptor antibody in primate renal transplantation.
30. On the identity of lymphoid cells that stimulate the rat MLC and produce active enhancement.
31. Detection of anti-donor "Ia" antibodies: a strong correlate of rejection.
32. Immunosuppression by anti-interleukin-2 receptor antibody but not anti-L3T4 requires terminal complement components.
33. Long-term results of cyclosporine treatment in renal transplantation.
34. Anti-interleukin-2 receptor (IL-2R) antibody against rejection of organ grafts.
35. Cyclosporin A plus fish oil: accentuate the positive, eliminate the negative.
36. Requirements for primary T cell activation.
37. Intragraft immune events causing vascularized organ graft rejection.
38. Four patterns of human renal allograft rejection: a cytologic and in vitro analysis of the infiltrate in 24 irreversibly rejected kidneys.
39. Accelerated graft loss: association with presensitization to donor B-cell (Ia) antigens.
40. Cyclic nucleotides in immunosuppression--neuroendocrine pharmacologic manipulation and in vivo immunoregulation of immunity acting via second messenger systems.
41. Passive enhancement of cadaver renal allografts: a prospective randomized trial of F(ab')2 therapy.
42. Immunotherapy using interleukin-2 diphtheria toxin chimer prolongs murine allografts.
43. HLA-D activity in lymphocyte subcellular fractions.
44. Suppression of in vivo and in vitro alloimmunity by prostaglandins.
45. Analysis of the subpopulations of T blasts bearing insulin receptors obtained by 1-g velocity sedimentation of murine mixed lymphocyte cultures.
46. Modification of the mixed lymphocyte reaction by alloactivated suppressor T lymphocytes and exogenous interleukin-2.
47. Therapeutic approach to renal transplantation: triple therapy and beyond.
48. Continuous density gradient separation of allosensitized cells from a mixed lymphocyte culture.
49. Anti-TAC MOAB prolongs renal allografts in cynomolgus monkeys.
50. Anti-T12 monoclonal antibody therapy of acute renal allograft rejection.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.